| Titolo |
Pubblicato in |
Anno |
| Predictive factors for response and survival in elderly acute myeloid
leukemia patients treated with hypomethylating agents: a real-life
experience |
ANNALS OF HEMATOLOGY |
2020 |
| The advantages and risks of ruxolitinib for the treatment of
polycythemia vera |
EXPERT REVIEW OF HEMATOLOGY |
2020 |
| Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients |
ANNALS OF HEMATOLOGY |
2020 |
| Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. |
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING |
2019 |
| Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. |
BLOOD |
2019 |
| Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma |
BRITISH JOURNAL OF HAEMATOLOGY |
2019 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy |
BLOOD |
2019 |
| Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding |
HEMATOLOGICAL ONCOLOGY |
2018 |
| Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma |
BLOOD |
2018 |
| Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death |
BRITISH JOURNAL OF HAEMATOLOGY |
2018 |
| Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma |
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
2017 |
| Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi |
THE LANCET. HAEMATOLOGY |
2017 |
| Primary mediastinal large B-cell lymphoma |
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
2017 |
| Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy. results from a monoinstitutional cohort analysis of long-term survivors |
HEMATOLOGICAL ONCOLOGY |
2017 |
| Cytological diagnostic features of late breast implant seromas. From reactive to anaplastic large cell lymphoma |
PLOS ONE |
2017 |
| In Reply to Adams and Kwee |
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
2017 |
| Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy |
JOURNAL OF CLINICAL ONCOLOGY |
2017 |
| Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study |
BRITISH JOURNAL OF HAEMATOLOGY |
2017 |
| Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study |
THE LANCET ONCOLOGY |
2017 |
| A MALT lymphoma prognostic index |
BLOOD |
2017 |
